Defunct Company
Total Trials
19
As Lead Sponsor
10
As Collaborator
9
Total Enrollment
6,320
NCT01490736
Phase 1/2 Sequentially Staged Safety Study in Healthy Subjects and Subjects With Mild Acne
Phase: Phase 1/2
Role: Lead Sponsor
Start: Dec 31, 2011
Completion: Jun 30, 2013
NCT01830764
Open-label Safety and Tolerability Study of LTS-PDT in Healthy Volunteers
Phase: Phase 1
Start: Apr 30, 2013
NCT01936324
A Safety, Tolerability and Preliminary Efficacy Study of DRM01B Topical Gel
Start: Aug 31, 2013
Completion: Jun 30, 2014
NCT01993420
A Safety and Efficacy of DRM02 in Subjects With Atopic Dermatitis
Phase: Phase 2
Start: Oct 31, 2013
Completion: Mar 31, 2014
NCT01993433
A Safety and Efficacy Study of DRM02 in Subjects With Plaque Psoriasis
NCT01993446
A Safety and Efficacy Study of DRM02 in Subjects With Rosacea
NCT02431052
A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris
Start: Apr 30, 2015
Completion: Apr 30, 2016
NCT03028363
A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
Phase: Phase 3
Start: Dec 27, 2016
Completion: Nov 28, 2017
NCT03073486
Start: Feb 6, 2017
Completion: Dec 21, 2017
NCT03127956
A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
Start: Mar 21, 2017
Completion: Apr 27, 2018
NCT03443024
A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis
Role: Collaborator
Start: Jan 30, 2018
Completion: May 23, 2019
NCT04146363
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)
Start: Sep 24, 2019
Completion: May 3, 2022
NCT04178967
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis
Start: Oct 29, 2019
Completion: Apr 28, 2022
NCT04250337
Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.
Start: Feb 3, 2020
Completion: Sep 16, 2021
NCT04250350
Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis
Start: Feb 11, 2020
Completion: Jun 22, 2022
NCT04392154
Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Start: Jun 15, 2020
Completion: Apr 22, 2025
NCT04788355
Prevention of Complications (SARS-CoV-2): Clinical Study
Start: Jul 1, 2020
Completion: Dec 23, 2020
NCT05559359
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Start: Oct 18, 2022
Completion: Dec 31, 2026
NCT06906497
Lebrikizumab in Moderate-to-severe Atopic Dermatitis
Phase: Phase 4
Start: Jul 2, 2025
Completion: Jul 31, 2027